Jon Napitupulu

Cytek Biosciences posted third-quarter 2025 revenue of $52.3 million, up 2% year over year, and expanded its installed base...

Kymera Therapeutics has completed enrollment and dosing in its Phase 1b BROADEN study of KT-621, a first-in-class, once-daily oral...

Avicanna has reshaped its board, accepting the resignation of director Paul Fornazzari and appointing capital-markets veteran Michael Kott effective...

Organogenesis has begun a rolling biologics license application with the FDA for Renu, a cryopreserved amniotic suspension allograft for...

Avicanna has announced a board transition, with Paul Fornazzari stepping down and Michael Kott joining as a director on...

Amneal Pharmaceuticals and Mabxience have secured FDA approvals for Boncresa (denosumab-mobz), a biosimilar to Prolia, and Oziltus (denosumab-mobz), a...

Organogenesis has initiated a rolling BLA submission to FDA for ReNu, a cryopreserved amniotic suspension allograft for symptomatic knee...

BioAtla secured FDA alignment on the design of its Phase 3 registrational study for ozuriftamab vedotin, a ROR2-targeting ADC,...

NRx Pharmaceuticals has refiled its ANDA for KETAFREE, a preservative-free ketamine injection, and reports supportive FDA correspondence pointing to...

Inotiv posted preliminary Q4 FY2025 revenue of $137.5–138.5 million and full-year FY2025 revenue of $512.5–513.5 million, alongside a Discovery...